Spinal Mechanisms of Pain and Analgesia

Pain Practice

Volumn 13, Issue 2, 2013, Pages 114-130

  Miljanich, George ^a   Rauck, Richard ^b   Saulino, Michael ^c  

^a Airmid Incorporated   (United States)

^b Center for Clinical Research   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Intrathecal analgesia; Pain mechanisms; Review

Indexed keywords

BACLOFEN; BUPIVACAINE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CLONIDINE; DELTA OPIATE RECEPTOR; DEXMEDETOMIDINE; DIAMORPHINE; GABAPENTIN; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; MIDAZOLAM; MORPHINE; MU OPIATE RECEPTOR; NORADRENALIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; PLACEBO; PREGABALIN; ROPIVACAINE; TIZANIDINE; YOHIMBINE;

ADD ON THERAPY; ALLODYNIA; ANALGESIA; ANTINOCICEPTION; APHASIA; ASTHENIA; BRADYCARDIA; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CEREBROSPINAL FLUID FLOW; CHRONIC PAIN; COGNITION; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EUPHORIA; FAILED BACK SURGERY SYNDROME; FOREBRAIN; GAIT DISORDER; GASTROINTESTINAL MOTILITY; HALLUCINATION; HIPPOCAMPUS; HUMAN; HYPERALGESIA; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INSOMNIA; LD 50; LOCAL ANESTHESIA; LOCUS CERULEUS; LONG TERM POTENTIATION; LOW BACK PAIN; MEMORY DISORDER; META ANALYSIS (TOPIC); MIXED PAIN; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NIGHTMARE; NOCICEPTION; NOCICEPTIVE PAIN; NONHUMAN; NYSTAGMUS; PAIN; PAIN THRESHOLD; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PERIPHERAL NERVE INJURY; PRESYNAPTIC MEMBRANE; PROTEIN PROCESSING; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; SPEECH DISORDER; SPINAL CORD DORSAL HORN; SPINAL CORD INJURY; SPINAL CORD NERVE CELL; SPINAL PAIN; SYNAPTIC TRANSMISSION; THINKING; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; URINARY DYSFUNCTION; VISCERAL PAIN; VISUAL ANALOG SCALE;

EID: 84873449674     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2012.00564.x     Document Type: Review

References (156)

1. Hardt J, Jacobsen C, Goldberg J, Nickel R, Buchwald D. Prevalence of chronic pain in a representative sample in the United States. Pain Med. 2008;9:803-812.
2. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
3. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443-2454.
4. Deer T, Krames ES, Hassenbusch SJ, et al.Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007;10:300-328.
5. Stein C, Clark JD, Oh U, et al.Peripheral mechanisms of pain and analgesia. Brain Res Rev. 2009;60:90-113.
6. Thomas Cheng H. Spinal cord mechanisms of chronic pain and clinical implications. Curr Pain Headache Rep. 2010;14:213-220.
7. Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature. 1985;316:440-443.
8. Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci. 1998;18:6319-6330.
9. Gohil K, Bell JR, Ramachandran J, Miljanich GP. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res. 1994;653:258-266.
10. Mintz IM, Adams ME, Bean BP. P-type calcium channels in rat central and peripheral neurons. Neuron. 1992;9:85-95.
11. Bowersox SS, Gadbois T, Singh T, Pettus M, Wang YX, Luther RR. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther. 1996;279:1243-1249.
12. Malmberg A, Yaksh T. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception. J Neurosci. 1994;14:4882-4890.
13. Omote K, Kawamata M, Satoh O, Iwasaki H, Namiki A. Spinal antinociceptive action of an N-type voltage-dependent calcium channel blocker and the synergistic interaction with morphine. Anesthesiology. 1996;84:636-643.
14. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther. 1994;269:1117-1123.
15. Sluka KA. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol Exp Ther. 1998;287:232-237.
16. Hatakeyama S, Wakamori M, Ino M, et al.Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. NeuroReport. 2001;12:2423-2427.
17. Kim C, Jun K, Lee T, et al.Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel. Mol Cell Neurosci. 2001;18:235-245.
18. Saegusa H, Kurihara T, Zong S, et al.Supapression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 2001;20:2349-2356.
19. Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 1995;35:707-734.
20. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139:267-284.
21. Zhuo M. Plasticity of NMDA receptor NR2B subunit in memory and chronic pain. Mol Brain. 2009;2:4.
22. Ikeda H, Stark J, Fischer H, et al.Synaptic amplifier of inflammatory pain in the spinal dorsal horn. Science. 2006;312:1659-1662.
23. Kieffer BL, Evans CJ. Opioid receptors: From binding sites to visible molecules in vivo. Neuropharmacology. 2009;56(Suppl 1):205-212.
24. Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand. 1997;41:94-111.
25. Arvidsson U, Riedl M, Chakrabarti S, et al.Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci. 1995;15(5 Pt 1):3328-3341.
26. Aicher SA, Sharma S, Cheng PY, Liu-Chen LY, Pickel VM. Dual ultrastructural localization of mu-opiate receptors and substance p in the dorsal horn. Synapse. 2000;36:12-20.
27. Pirec V, Laurito CE, Lu Y, Yeomans DC. The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. Anesth Analg. 2001;92:239-243.
28. Arvidsson U, Dado RJ, Riedl M, et al.delta-Opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. J Neurosci. 1995;15:1215-1235.
29. Bailey A, Ledent C, Kelly M, Hourani SMO, Kitchen I. Changes in spinal δ and κ opioid systems in mice deficient in the A2A receptor gene. J Neurosci. 2002;22:9210-9220.
30. Wu ZZ, Chen SR, Pan HL. Differential sensitivity of N- and P/Q-type Ca2+ channel currents to a mu opioid in isolectin B4-positive and -negative dorsal root ganglion neurons. J Pharmacol Exp Ther. 2004;311:939-947.
31. Connor M, Christie MJ. Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons. J Physiol. 1998;509(Pt 1):47-58.
32. Noble F, Cox BM. Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol. 1996;117:161-169.
33. Marker CL, Lujan R, Loh HH, Wickman K. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. J Neurosci. 2005;25:3551-3559.
34. Witkowski G, Szulczyk P. Opioid mu receptor activation inhibits sodium currents in prefrontal cortical neurons via a protein kinase A- and C-dependent mechanism. Brain Res. 2006;1094:92-106.
35. Hassenbusch SJ, Stanton-Hicks M, Covington EC, Walsh JG, Guthrey DS. Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage. 1995;10:527-543.
36. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage. 1996;11:71-80.
37. Angel IF, Gould HJ Jr, Carey ME. Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg Neurol. 1998;49:92-98; discussion 98-99.
38. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999;44:289-300; discussion 300-301.
39. Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med. 2001;2:287-297.
40. Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003;4:441-447.
41. Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain. 2004;109:242-249.
42. Atli A, Theodore BR, Turk DC, Loeser JD. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. Pain Med. 2010;11:1010-1016.
43. Winkelmuller M, Winkelmuller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996;85:458-467.
44. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant Pain: a double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromudulation. 2002;5:208-213.
45. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol. 2001;55:79-86; discussion 86-88.
46. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18(4 Suppl):S3-13.
47. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 2008;154:384-396.
48. Joo DT. Mechanisms of opioid tolerance: merging evidence and therapeutic implications. Can J Anaesth. 2007;54:969-976.
49. Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol. 2008;153(Suppl 1):S379-388.
50. Koch T, Hollt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther. 2008;117:199-206.
51. Dang VC, Napier IA, Christie MJ. Two distinct mechanisms mediate acute mu-opioid receptor desensitization in native neurons. J Neurosci. 2009;29:3322-3327.
52. Porreca F, Burks TF. The spinal cord as a site of opioid effects on gastrointestinal transit in the mouse. J Pharmacol Exp Ther. 1983;227:22-27.
53. Snyder SH. Opiate receptors in the brain. N Engl J Med. 1977;296:266-271.
54. Colameco S, Coren JS. Opioid-induced endocrinopathy. J Am Osteopath Assoc. 2009;109:20-25.
55. Kristipati R, Nadasdi L, Tarczy-Hornoch K, et al.Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels. Mol Cell Neurosci. 1994;5:219-228.
56. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004;11:3029-3040.
57. McCleskey EW, Fox AP, Feldman DH, et al.Omega-conotoxin: direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc Natl Acad Sci USA. 1987;84:4327-4331.
58. Dooley DJ, Lupp A, Hertting G. Inhibition of central neurotransmitter release by omega-conotoxin GVIA, a peptide modulator of the N-type voltage-sensitive calcium channel. Naunyn Schmiedebergs Arch Pharmacol. 1987;336:467-470.
59. Yeager RE, Yoshikami D, Rivier J, Cruz LJ, Miljanich GP. Transmitter release from presynaptic terminals of electric organ: inhibition by the calcium channel antagonist omega Conus toxin. J Neurosci. 1987;7:2390-2396.
60. Holz GGt, Dunlap K, Kream RM. Characterization of the electrically evoked release of substance P from dorsal root ganglion neurons: methods and dihydropyridine sensitivity. J Neurosci. 1988;8:463-471.
61. Santicioli P, Del Bianco E, Tramontana M, Geppetti P, Maggi CA. Release of calcitonin gene-related peptide like-immunoreactivity induced by electrical field stimulation from rat spinal afferents is mediated by conotoxin-sensitive calcium channels. Neurosci Lett. 1992;136:161-164.
62. Maggi CA, Tramontana M, Cecconi R, Santicioli P. Neurochemical evidence for the involvement of N-type calcium channels in transmitter secretion from peripheral endings of sensory nerves in guinea pigs. Neurosci Lett. 1990;114:203-206.
63. Gruner W, Silva LR. Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro. J Neurosci. 1994;14(5 Pt 1):2800-2808.
64. Staats PS, Yearwood T, Charapata SG, et al.Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63-70.
65. Wallace MS, Charapata SG, Fisher R, et al.Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9:75-86.
66. Rauck RL, Wallace MS, Leong MS, et al.A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393-406.
67. Raffaeli W, Sarti D, Demartini L, Sotgiu A, Bonezzi C. Italian registry on long-term intrathecal ziconotide treatment. Pain Physician. 2011;14:15-24.
68. Ellis DJ, Dissanayake S, McGuire D, et al.Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12months: a prospective, open-label study. Neuromodulation. 2008;11:40-49.
69. Webster LR, Fisher R, Charapata S, Wallace MS. Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage. 2009;37:363-372.
70. Burton AW, Deer TR, Wallace MS, Rauck RL, Grigsby E. Considerations and methodology for trialing ziconotide. Pain Physician. 2010;13:23-33.
71. Wermeling D, Drass M, Ellis D, et al.Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003;43:624-636.
72. ® (ziconotide intrathecal infusion) [product insert]. Philadelphia, PA: Azur Pharmaceuticals Inc; 2010.
73. Kerr LM, Filloux F, Olivera BM, Jackson H, Wamsley JK. Autoradiographic localization of calcium channels with [125I]omega-conotoxin in rat brain. Eur J Pharmacol. 1988;146:181-183.
74. Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag. 2009;5:521-534.
75. Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain. 2010;26:635-644.
76. Webster LR, Fakata KL, Charapata S, Fisher R, MineHart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med. 2008;9:282-290.
77. Wallace MS, Kosek PS, Staats P, Fisher R, Schultz DM, Leong M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008;9:271-281.
78. Marais E, Klugbauer N, Hofmann F. Calcium channel alpha(2)delta subunits-structure and Gabapentin binding. Mol Pharmacol. 2001;59:1243-1248.
79. Field MJ, Cox PJ, Stott E, et al.Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103:17537-17542.
80. Taylor CP, Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (alpha2-delta) type 1 protein. Neuroscience. 2008;155:510-521.
81. Andrade A, Sandoval A, Gonzalez-Ramirez R, Lipscombe D, Campbell KP, Felix R. The alpha(2)delta subunit augments functional expression and modifies the pharmacology of Ca(V)1.3L-type channels. Cell Calcium. 2009;46:282-292.
82. Canti C, Nieto-Rostro M, Foucault I, et al.The metal-ion-dependent adhesion site in the Von Willebrand factor-A domain of alpha2delta subunits is key to trafficking voltage-gated Ca2+ channels. Proc Natl Acad Sci USA. 2005;102:11230-11235.
83. Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res. 2001;95:1-8.
84. Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004;24:8494-8499.
85. Narita M, Nakajima M, Miyoshi K, et al.Role of spinal voltage-dependent calcium channel alpha 2 delta-1 subunit in the expression of a neuropathic pain-like state in mice. Life Sci. 2007;80:2015-2024.
86. Boroujerdi A, Zeng J, Sharp K, Kim D, Steward O, Luo ZD. Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. Pain. 2011;152:649-655.
87. Bauer CS, Nieto-Rostro M, Rahman W, et al.The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci. 2009;29:4076-4088.
88. Costigan M, Befort K, Karchewski L, et al.Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci. 2002;3:16.
89. Wang H, Sun H, Della Penna K, et al.Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. Neuroscience. 2002;114:529-546.
90. Boroujerdi A, Kim HK, Lyu YS, et al.Injury discharges regulate calcium channel alpha-2-delta-1 subunit upregulation in the dorsal horn that contributes to initiation of neuropathic pain. Pain. 2008;139:358-366.
91. Li CY, Zhang XL, Matthews EA, et al.Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125:20-34.
92. Tuchman M, Barrett JA, Donevan S, Hedberg TG, Taylor CP. Central sensitization and Ca(V)alphadelta ligands in chronic pain syndromes: pathologic processes and pharmacologic effect. J Pain. 2010;11:1241-1249.
93. Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology. 1998;37:83-91.
94. Uchitel OD, Di Guilmi MN, Urbano FJ, Gonzalez-Inchauspe C. Acute modulation of calcium currents and synaptic transmission by gabapentinoids. Channels (Austin). 2010;4:490-496.
95. Fink K, Dooley DJ, Meder WP, et al.Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229-236.
96. Takasusuki T, Yaksh TL. The effects of intrathecal and systemic gabapentin on spinal substance p release. Anesth Analg. 2011;112:971-976.
97. Hendrich J, Van Minh AT, Heblich F, et al.Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA. 2008;105:3628-3633.
98. Tran-Van-Minh A, Dolphin AC. The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2. J Neurosci. 2010;30:12856-12867.
99. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105:133-141.
100. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75-82.
101. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137-150.
102. Bee LA, Dickenson AH. Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. Pain. 2008;140:209-223.
103. Hayashida K, Obata H, Nakajima K, Eisenach JC. Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Anesthesiology. 2008;109:1077-1084.
104. Tanabe M, Takasu K, Takeuchi Y, Ono H. Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury. J Neurosci Res. 2008;86:3258-3264.
105. Rahman W, Bauer CS, Bannister K, Vonsy JL, Dolphin AC, Dickenson AH. Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Mol Pain. 2009;5:45.
106. Burgess SE, Gardell LR, Ossipov MH, et al.Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci. 2002;22:5129-5136.
107. Hayashida K, DeGoes S, Curry R, Eisenach JC. Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. Anesthesiology. 2007;106:557-562.
108. Takeuchi Y, Takasu K, Ono H, Tanabe M. Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology. 2007;53:842-853.
109. Takeuchi Y, Takasu K, Honda M, Ono H, Tanabe M. Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. Eur J Pharmacol. 2007;556:69-74.
110. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;3:CD007938.
111. Chu LC, Tsaur ML, Lin CS, et al.Chronic intrathecal infusion of gabapentin prevents nerve ligation-induced pain in rats. Br J Anaesth. 2011;106:699-705.
112. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826-836.
113. Asano T, Dohi S, Ohta S, Shimonaka H, Iida H. Antinociception by epidural and systemic alpha(2)-adrenoceptor agonists and their binding affinity in rat spinal cord and brain. Anesth Analg. 2000;90:400-407.
114. Gabriel JS, Gordin V. Alpha 2 agonists in regional anesthesia and analgesia. Curr Opin Anaesthesiol. 2001;14:751-753.
115. Stone LS, Broberger C, Vulchanova L, et al.Differential distribution of alpha2A and alpha2C adrenergic receptor immunoreactivity in the rat spinal cord. J Neurosci. 1998;18:5928-5937.
116. Khan ZP, Ferguson CN, Jones RM. alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999;54:146-165.
117. Wolff M, Heugel P, Hempelmann G, Scholz A, Muhling J, Olschewski A. Clonidine reduces the excitability of spinal dorsal horn neurones. Br J Anaesth. 2007;98:353-361.
118. Bantel C, Eisenach JC, Duflo F, Tobin JR, Childers SR. Spinal nerve ligation increases alpha2-adrenergic receptor G-protein coupling in the spinal cord. Brain Res. 2005;1038:76-82.
119. Li X, Eisenach JC. alpha2A-adrenoceptor stimulation reduces capsaicin-induced glutamate release from spinal cord synaptosomes. J Pharmacol Exp Ther. 2001;299:939-944.
120. Ge YX, Xin WJ, Hu NW, Zhang T, Xu JT, Liu XG. Clonidine depresses LTP of C-fiber evoked field potentials in spinal dorsal horn via NO-cGMP pathway. Brain Res. 2006;1118:58-65.
121. Roh DH, Kim HW, Yoon SY, et al.Intrathecal clonidine supapresses phosphorylation of the N-methyl-d-aspartate receptor NR1 subunit in spinal dorsal horn neurons of rats with neuropathic pain. Anesth Analg. 2008;107:693-700.
122. Buerkle H, Schapsmeier M, Bantel C, Marcus MA, Wusten R, Van Aken H. Thermal and mechanical antinociceptive action of spinal vs peripherally administered clonidine in the rat inflamed knee joint model. Br J Anaesth. 1999;83:436-441.
123. Ono N, Kroin JS, Penn RD, Paice JA. Effects of intrathecal nonnarcotic analgesics on chronic tactile allodynia in rats: alpha 2-agonists versus somatostatin analog. Neurol Med Chir (Tokyo). 1997;37:6-10; discussion 10-11.
124. Gomes JA, Li X, Pan HL, Eisenach JC. Intrathecal adenosine interacts with a spinal noradrenergic system to produce antinociception in nerve-injured rats. Anesthesiology. 1999;91:1072-1079.
125. Blake DW, Scott DA, Angus JA, Wright CE. Synergy between intrathecal omega-conotoxin CVID and dexmedetomidine to attenuate mechanical hypersensitivity in the rat. Eur J Pharmacol. 2005;506:221-227.
126. Hassenbusch SJ, Garber J, Buchser E, Du Pen S, Nitescu P. Alternative intrathecal agents for the treatment of pain. Neuromodulation. 1999;2:85-91.
127. Siddall PJ, Molloy AR, Walker S, Mather LE, Rutkowski SB, Cousins MJ. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg. 2000;91:1493-1498.
128. Borg PA, Krijnen HJ. Long-term intrathecal administration of midazolam and clonidine. Clin J Pain. 1996;12:63-68.
129. Middleton JW, Siddall PJ, Walker S, Molloy AR, Rutkowski SB. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil. 1996;77:824-826.
130. Coombs DW, Saunders RL, Fratkin JD, Jensen LE, Murphy CA. Continuous intrathecal hydromorphone and clonidine for intractable cancer pain. J Neurosurg. 1986;64:890-894.
131. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage. 2003;26:668-677.
132. Rainov NG, Heidecke V, Burkert W. Long-term intrathecal infusion of drug combinations for chronic back and leg pain. J Pain Symptom Manage. 2001;22:862-871.
133. Raphael JH, Southall JL, Gnanadurai TV, Treharne GJ, Kitas GD. Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain. BMC Musculoskelet Disord. 2002;3:17.
134. Lawson E, Wallace M. Current developments in intraspinal agents for cancer and noncancer pain. Curr Pain Headache Rep. 2010;14:8-16.
135. Tiplady B, Bowness E, Stien L, Drummond G. Selective effects of clonidine and temazepam on attention and memory. J Psychopharmacol. 2005;19:259-265.
136. Bevacqua BK, Fattouh M, Backonja M. Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy. Pain Pract. 2007;7:36-38.
137. Sabbe MB, Penning JP, Ozaki GT, Yaksh TL. Spinal and systemic action of the alpha 2 receptor agonist dexmedetomidine in dogs. Antinociception and carbon dioxide response. Anesthesiology. 1994;80:1057-1072.
138. Buerkle H, Yaksh TL. Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth. 1998;81:208-215.
139. Eisenach J, Detweiler D, Hood D. Hemodynamic and analgesic actions of epidurally administered clonidine. Anesthesiology. 1993;78:277-287.
140. Eisenach JC, Hood DD, Curry R. Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia. Pain. 2000;84:57-64.
141. Eisenach JC, Hood DD, Curry R. Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. Anesth Analg. 1998;87:591-596.
142. Scholz A, Kuboyama N, Hempelmann G, Vogel W. Complex blockade of TTX-resistant Na+ currents by lidocaine and bupivacaine reduce firing frequency in DRG neurons. J Neurophysiol. 1998;79:1746-1754.
143. Bräu ME, Elliott JR. Local anaesthetic effects on tetrodotoxin-resistant Na+ currents in rat dorsal root ganglion neurones. Eur J Anaesthesiol. 1998;15:80-88.
144. Fjell J, Hjelmström P, Hormuzdiar W, et al.Localization of the tetrodotoxin-resistant sodium channel NaN in nociceptors. NeuroReport. 2000;11:199-202.
145. Oda A, Ohashi H, Komori S, Iida H, Dohi S. Characteristics of ropivacaine block of Na+ channels in rat dorsal root ganglion neurons. Anesth Analg. 2000;91:1213-1220.
146. Olschewski A, Wolff M, Bräu ME, Hempelmann G, Vogel W, Safronov BV. Enhancement of delayed-rectifier potassium conductance by low concentrations of local anaesthetics in spinal sensory neurones. Br J Pharmacol. 2002;136:540-549.
147. Ueta K, Sugimoto M, Suzuki T, Uchida I, Mashimo T. In vitro antagonism of recombinant ligand-gated ion-channel receptors by stereospecific enantiomers of bupivacaine. Reg Anesth Pain Med. 2006;31:19-25.
148. Deer TR, Serafini M, Buchser E, Ferrante FM, Hassenbusch SJ. Intrathecal bupivacaine for chronic pain: a review of current knowledge. Neuromodulation. 2002;5:196-207.
149. Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002;2:274-278.
150. Kumar K, Bodani V, Bishop S, Tracey S. Use of intrathecal bupivacaine in refractory chronic nonmalignant pain. Pain Med. 2009;10:819-828.
151. Gupta R, Bogra J, Verma R, Kohli M, Kushwaha JK, Kumar S. Dexmedetomidine as an intrathecal adjuvant for postoperative analgesia. Indian J Anaesth. 2011;55:347-351.
152. McCall TD, MacDonald JD. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery. 2006;59:634-640; discussion 634-640.
153. Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology. 2010;112:165-173.
154. Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg. 2011;112:460-464.
155. Hejtmanek MR, Harvey TD, Bernards CM. Measured density and calculated baricity of custom-compounded drugs for chronic intrathecal infusion. Reg Anesth Pain Med. 2011;36:7-11.
156. Perruchoud C, Eldabe S, Durrer A, et al.Effects of flow rate modifications on reported analgesia and quality of life in chronic pain patients treated with continuous intrathecal drug therapy. Pain Med. 2011;12:571-576.